JSAM
PCVX icon

J. Safra Asset Management’s Vaxcyte PCVX Stock Holding History

J. Safra Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$730K Buy
12,564
+1,714
+16% +$93.1K 0.03% 143
2026
Q1 		$630K Buy
10,850
+3,796
+54% +$206K 0.03% 145
2025
Q4 		$325K Buy
7,054
+1,070
+18% +$47.9K 0.02% 185
2025
Q3 		$216K Buy
5,984
+1,912
+47% +$63.3K 0.01% 166
2025
Q2 		$132K Buy
4,072
+669
+20% +$21.9K 0.01% 174
2025
Q1 		$128K Buy
3,403
+1,496
+78% +$120K 0.01% 158
2024
Q4 		$156K Buy
1,907
+736
+63% +$73.1K 0.01% 141
2024
Q3 		$132K Buy
1,171
+564
+93% +$50.8K 0.01% 101
2024
Q2 		$45.8K Buy
607
+526
+649% +$35.8K ﹤0.01% 147
2024
Q1 		$5.53K Buy
+81
New +$5.61K ﹤0.01% 153

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

J. Safra Asset Management's PCVX Position: Q2 2026 in Review

J. Safra Asset Management increased its Vaxcyte (PCVX) stake by 16% in Q2 2026, buying an estimated $93.1K and bringing the position to 12,564 shares worth $730K. The position accounts for 0.03% of the portfolio, ranked #143.

J. Safra Asset Management first reported a position in PCVX in Q1 2024 and has held it in 10 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • J. Safra Asset Management held 12,564 shares of Vaxcyte worth $730K as of Q2 2026.
  • J. Safra Asset Management bought 1,714 Vaxcyte shares in Q2 2026, an estimated $93.1K.
  • Vaxcyte made up 0.03% of J. Safra Asset Management's portfolio in Q2 2026, its #143 holding.
  • J. Safra Asset Management first reported a position in Vaxcyte in Q1 2024 and has held it in 10 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.